<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00182221</url>
  </required_header>
  <id_info>
    <org_study_id>CTMG-2005-SIMPLE</org_study_id>
    <secondary_id>Grant #NA 5154</secondary_id>
    <nct_id>NCT00182221</nct_id>
  </id_info>
  <brief_title>Safety of a Diagnostic Strategy With D-Dimer Testing for PE</brief_title>
  <official_title>A Cohort Study Evaluating the Safety of a Diagnostic Strategy Involving D-Dimer Testing in Patients With Suspected Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether D-Dimer testing, using the MDA D-Dimer assay, can be used to simplify
      the diagnostic process for pulmonary embolism (PE). This will be assessed by performing a
      cohort study in 1000 patients with suspected PE.

      To ascertain if an MDA D-Dimer result of less than 0.75 ug/mL FEU obviates the need for
      further testing and therapy in patients with suspected PE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective cohort study of 1000 patients in which those with a negative D-Dimer result
      undergo no further testing and are followed for 3 months for venous thromboembolism. Patients
      with a positive D-Dimer undergo standardized testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venousthromboembolism</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Venous Thromboembolism</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MDA D-Dimer Testing</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Suspected PE

        Exclusion Criteria:

          -  Treatment with full-dose anticoagulants for 24 hours or more OR an ongoing requirement
             for anticoagulants

          -  Other tests for PE performed prior to eligibility assessment (e.g.other D-Dimer, V/Q
             scan, pulmonary angiogram, spiral CT, compression ultrasound, venogram).

          -  Cardiorespiratory instability requiring immediate performance of other tests to
             diagnose or exclude PE (i.e. inability to wait 30-60 minutes for MDA D-Dimer result)

          -  Comorbid condition limiting survival to less than three months

          -  Patient has been asymptomatic for seven days prior to presentation

          -  Current pregnancy

          -  Contraindication to contrast (e.g., allergy, renal failure).

          -  Geographic in accessibility which precludes follow-up

          -  Presence of central venous catheter (permanent or temporary, including PICC line) at
             the time of eligibility assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon M Bates, MDCM,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Joseph's Health Care Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences-Henderson Campus</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V !C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences-McMaster Campus</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences, General</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>MDA D-Dimer Testing</keyword>
  <keyword>Diagnostic Algorithm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

